Ampliphi Biosciences Corp (APHB) 0.1950 $APHB
AmpliPhi BioSciences elects M. Scott Salka as new CEO
M2 - Mon May 04, 3:40AM CDT
Antibacterial therapies company AmpliPhi BioSciences (OtherOTC:APHB) disclosed on Friday the addition of M. Scott Salka as its new chief executive officer effective 18 May 2015.
New chief at AmpliPhi Bio
Seeking Alpha - at Seeking Alpha - Fri May 01, 9:15AM CDT
AmpliPhi BioSciences Announces M. Scott Salka as New CEO
Business Wire - Thu Apr 30, 8:00PM CDT
AmpliPhi BioSciences Corporation (OTCQB:APHB), a global leader in developing bacteriophage-based antibacterial therapies to treat drug resistant infections, today announced that M. Scott Salka has been appointed as the new CEO. Mr. Salka will replace Interim CEO and Chairman of AmpliPhi, Jeremy Curnock Cook, effective May 18. Mr. Curnock Cook will remain in his role as Chairman.
XON: 40.86 (+0.78)
Guarding Against A Possible Biotech Correction
Lowenthal Capital Partners - at Seeking Alpha - Wed Apr 29, 10:58AM CDT
SYN: 1.88 (+0.01), SNTA: 2.34 (+0.01), RNN: 0.70 (-0.01), OPK: 16.99 (+0.07), CLDN: 2.20 (+0.02), IBB: 357.26 (+1.65), AAVL: 35.69 (+0.59)
Heavy Insider Buying In These Biotechs: Is It Time To Follow Suit?
Lowenthal Capital Partners - at Seeking Alpha - Mon Apr 20, 7:42AM CDT
SNTA: 2.34 (+0.01), XON: 40.86 (+0.78)
Penny Stocks Alerts for Thinspace Technology, Genius Brands International, Blue Calypso, Laredo Oil, Ampliphi Biosciences, and Green Technology Solutions
PR Newswire - Tue Apr 07, 7:45AM CDT
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: Thinspace Technology (OTCMKTS:THNS), Genius Brands International (OTCBB:GNUS), Blue Calypso (OTCMKTS:BCYP), Laredo Oil (OTCMKTS:LRDC), Ampliphi Biosciences (OTCMKTS:APHB), and Green Technology Solutions (OTCMKTS:GTSO).
AmpliPhi Granted European Patent for Bacteriophage Therapy to Fight Biofilm-related Bacterial Infections
Business Wire - Tue Mar 31, 6:00AM CDT
AmpliPhi BioSciences Corporation (OTCQB:APHB), the global leader in developing bacteriophage-based antibacterial therapies to treat drug resistant infections, today announced that the European Patent Office (EPO) has granted European patent no. EP 2570130, "Bacteriophage-containing Therapeutic Agents". Three related patents have been issued in the United States (U.S. Patent Nos. 7,807,149, 8,105,579, and 8,388,946), the earliest of which was previously granted in 2010.
XON: 40.86 (+0.78)
InsiderInsights.com Daily Round Up 3/18/15: DO, ASPS, CGIX, ADMA
InsiderInsights - at Seeking Alpha - Thu Mar 19, 11:55AM CDT
MPW: 13.80 (-0.01), SSNC: 60.08 (+0.44), SANW: 4.86 (-0.13), ADMA: 8.06 (-0.19), ASPS: 29.63 (-0.63), MMI: 44.66 (+0.27), PSA: 200.30 (+0.23), ENOC: 9.88 (-0.07), PCLN: 1,205.08 (+6.28), CGIX: 10.77 (+0.02), FDS: 165.02 (-0.23), GGP: 28.31 (-0.19), NEE: 102.01 (-0.13), DO: 32.81 (-0.31), RXDX: 9.09 (-0.12), DYN: 33.55 (-0.30), TCB: 15.62 (+0.04), TWTR: 37.48 (+0.38), RGS: 16.63 (-0.02)
AmpliPhi Bio raises $13M in new capital
Seeking Alpha - at Seeking Alpha - Wed Mar 11, 6:40AM CDT
XON: 40.86 (+0.78)
AmpliPhi BioSciences concludes USD13m financing
M2 - Wed Mar 11, 5:26AM CDT
Bacteriophage therapies company AmpliPhi BioSciences (OtherOTC:APHB) announced on Tuesday that it expects to raise approximately USD13m in a private placement financing of common stock and warrants with both existing and new investors, as well as with its strategic alliance partner Intrexon (NYSE:XON).
XON: 40.86 (+0.78)
AmpliPhi BioSciences Corporation Announces $13 Million Financing
Business Wire - Tue Mar 10, 4:07PM CDT
AmpliPhi BioSciences Corporation, (OTCQB: APHB), a global leader in bacteriophage-based antibacterial therapies to treat drug resistant infections, announced today that it has entered into definitive purchase agreements of common stock and warrants with a group of institutional accredited investors, including both existing and new investors, as well as with its strategic alliance partner Intrexon (NYSE: XON), to raise approximately $13,000,000 in a private placement financing. Pursuant to the purchase agreements, the Company will issue an aggregate of 78,787,880 shares of the Company's common stock at a price per share of $0.165, as well as the sale and issuance of warrants to purchase 0.25 shares of common stock for each share of common stock per warrant share. The warrants, which represent the right to purchase an aggregate of 19,696,971 shares of common stock, expire in March 2020 and will be exercisable at a price of $0.215 per share. The warrants will be exercisable beginning on the later of (i) the first anniversary of the date of issuance and (ii) the date AmpliPhi effects a reverse stock split or increases the number of authorized shares of common stock, in either case in an amount sufficient to permit the exercise in full of the warrants issued in this offering. If the reverse stock split or share increase occurs before the first anniversary, the warrants will be exercisable at that time.
XON: 40.86 (+0.78)
AmpliPhi Biosciences to restate financials for four quarters
Seeking Alpha - at Seeking Alpha - Mon Mar 09, 6:44AM CDT
AmpliPhi Update: Key Highlights From The Shareholder Conference Call
Trevor Lowenthal - at Seeking Alpha - Tue Jan 06, 10:57AM CST
AmpliPhi Provides Shareholder Update
Business Wire - Mon Jan 05, 7:29PM CST
--2015 Uplisting to Major Exchange Expected
XON: 40.86 (+0.78)
AmpliPhi Bio to host shareholder update
Seeking Alpha - at Seeking Alpha - Wed Dec 31, 6:28AM CST
AmpliPhi BioSciences to Host Shareholder Update Conference Call
Business Wire - Tue Dec 30, 6:11PM CST
AmpliPhi BioSciences Corporation (OTCQB:APHB) ("AmpliPhi"
, the leader in the discovery and development of bacteriophage based therapies to treat drug resistant bacterial infections, today announced that it will host a shareholder update conference call on Monday, January 05, 2015 at 4:15 PM ET.
XON: 40.86 (+0.78)
Intrexon Corporation Has Two Overlooked Opportunities In The Anti-Infective Space
Trevor Lowenthal - at Seeking Alpha - Mon Dec 29, 11:51AM CST
XON: 40.86 (+0.78), OGEN: 0.80 (-0.03)
Update: AmpliPhi Is Making Important Moves To Advance Its Anti-Infective Pipeline
Trevor Lowenthal - at Seeking Alpha - Fri Dec 26, 10:55PM CST
Acinetobacter Infections - Pipeline Review, H1 2014
M2 - Mon Dec 08, 3:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/5pbmng/acinetobacter) has announced the addition of the "Acinetobacter Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Acinetobacter Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acinetobacter Infections and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Acinetobacter Infections - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Acinetobacter Infections pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - AmpliPhi Biosciences - Melinta Therapeutics - Pfizer - Sarepta Therapeutics - Achaogen - Evolva - Novabiotics - Aridis Pharmaceuticals - FOB Synthesis - Synthetic Biologics - Trana Discovery - Cantab Biopharmaceuticals - Omnia Molecular - Northern Antibiotics - Nosopharm - Adenium Biotech - Vaxdyn For more information visit http://www.researchandmarkets.com/research/5p...netobacter
SYN: 1.88 (+0.01), SRPT: 15.40 (+0.19)
Update: AmpliPhi Q3 Earnings
Trevor Lowenthal - at Seeking Alpha - Wed Nov 19, 12:14AM CST
AmpliPhi BioSciences elects M. Scott Salka as new CEO
M2 - Mon May 04, 3:40AM CDT
Antibacterial therapies company AmpliPhi BioSciences (OtherOTC:APHB) disclosed on Friday the addition of M. Scott Salka as its new chief executive officer effective 18 May 2015.
New chief at AmpliPhi Bio
Seeking Alpha - at Seeking Alpha - Fri May 01, 9:15AM CDT
AmpliPhi BioSciences Announces M. Scott Salka as New CEO
Business Wire - Thu Apr 30, 8:00PM CDT
AmpliPhi BioSciences Corporation (OTCQB:APHB), a global leader in developing bacteriophage-based antibacterial therapies to treat drug resistant infections, today announced that M. Scott Salka has been appointed as the new CEO. Mr. Salka will replace Interim CEO and Chairman of AmpliPhi, Jeremy Curnock Cook, effective May 18. Mr. Curnock Cook will remain in his role as Chairman.
XON: 40.86 (+0.78)
Guarding Against A Possible Biotech Correction
Lowenthal Capital Partners - at Seeking Alpha - Wed Apr 29, 10:58AM CDT
SYN: 1.88 (+0.01), SNTA: 2.34 (+0.01), RNN: 0.70 (-0.01), OPK: 16.99 (+0.07), CLDN: 2.20 (+0.02), IBB: 357.26 (+1.65), AAVL: 35.69 (+0.59)
Heavy Insider Buying In These Biotechs: Is It Time To Follow Suit?
Lowenthal Capital Partners - at Seeking Alpha - Mon Apr 20, 7:42AM CDT
SNTA: 2.34 (+0.01), XON: 40.86 (+0.78)
Penny Stocks Alerts for Thinspace Technology, Genius Brands International, Blue Calypso, Laredo Oil, Ampliphi Biosciences, and Green Technology Solutions
PR Newswire - Tue Apr 07, 7:45AM CDT
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: Thinspace Technology (OTCMKTS:THNS), Genius Brands International (OTCBB:GNUS), Blue Calypso (OTCMKTS:BCYP), Laredo Oil (OTCMKTS:LRDC), Ampliphi Biosciences (OTCMKTS:APHB), and Green Technology Solutions (OTCMKTS:GTSO).
AmpliPhi Granted European Patent for Bacteriophage Therapy to Fight Biofilm-related Bacterial Infections
Business Wire - Tue Mar 31, 6:00AM CDT
AmpliPhi BioSciences Corporation (OTCQB:APHB), the global leader in developing bacteriophage-based antibacterial therapies to treat drug resistant infections, today announced that the European Patent Office (EPO) has granted European patent no. EP 2570130, "Bacteriophage-containing Therapeutic Agents". Three related patents have been issued in the United States (U.S. Patent Nos. 7,807,149, 8,105,579, and 8,388,946), the earliest of which was previously granted in 2010.
XON: 40.86 (+0.78)
InsiderInsights.com Daily Round Up 3/18/15: DO, ASPS, CGIX, ADMA
InsiderInsights - at Seeking Alpha - Thu Mar 19, 11:55AM CDT
MPW: 13.80 (-0.01), SSNC: 60.08 (+0.44), SANW: 4.86 (-0.13), ADMA: 8.06 (-0.19), ASPS: 29.63 (-0.63), MMI: 44.66 (+0.27), PSA: 200.30 (+0.23), ENOC: 9.88 (-0.07), PCLN: 1,205.08 (+6.28), CGIX: 10.77 (+0.02), FDS: 165.02 (-0.23), GGP: 28.31 (-0.19), NEE: 102.01 (-0.13), DO: 32.81 (-0.31), RXDX: 9.09 (-0.12), DYN: 33.55 (-0.30), TCB: 15.62 (+0.04), TWTR: 37.48 (+0.38), RGS: 16.63 (-0.02)
AmpliPhi Bio raises $13M in new capital
Seeking Alpha - at Seeking Alpha - Wed Mar 11, 6:40AM CDT
XON: 40.86 (+0.78)
AmpliPhi BioSciences concludes USD13m financing
M2 - Wed Mar 11, 5:26AM CDT
Bacteriophage therapies company AmpliPhi BioSciences (OtherOTC:APHB) announced on Tuesday that it expects to raise approximately USD13m in a private placement financing of common stock and warrants with both existing and new investors, as well as with its strategic alliance partner Intrexon (NYSE:XON).
XON: 40.86 (+0.78)
AmpliPhi BioSciences Corporation Announces $13 Million Financing
Business Wire - Tue Mar 10, 4:07PM CDT
AmpliPhi BioSciences Corporation, (OTCQB: APHB), a global leader in bacteriophage-based antibacterial therapies to treat drug resistant infections, announced today that it has entered into definitive purchase agreements of common stock and warrants with a group of institutional accredited investors, including both existing and new investors, as well as with its strategic alliance partner Intrexon (NYSE: XON), to raise approximately $13,000,000 in a private placement financing. Pursuant to the purchase agreements, the Company will issue an aggregate of 78,787,880 shares of the Company's common stock at a price per share of $0.165, as well as the sale and issuance of warrants to purchase 0.25 shares of common stock for each share of common stock per warrant share. The warrants, which represent the right to purchase an aggregate of 19,696,971 shares of common stock, expire in March 2020 and will be exercisable at a price of $0.215 per share. The warrants will be exercisable beginning on the later of (i) the first anniversary of the date of issuance and (ii) the date AmpliPhi effects a reverse stock split or increases the number of authorized shares of common stock, in either case in an amount sufficient to permit the exercise in full of the warrants issued in this offering. If the reverse stock split or share increase occurs before the first anniversary, the warrants will be exercisable at that time.
XON: 40.86 (+0.78)
AmpliPhi Biosciences to restate financials for four quarters
Seeking Alpha - at Seeking Alpha - Mon Mar 09, 6:44AM CDT
AmpliPhi Update: Key Highlights From The Shareholder Conference Call
Trevor Lowenthal - at Seeking Alpha - Tue Jan 06, 10:57AM CST
AmpliPhi Provides Shareholder Update
Business Wire - Mon Jan 05, 7:29PM CST
--2015 Uplisting to Major Exchange Expected
XON: 40.86 (+0.78)
AmpliPhi Bio to host shareholder update
Seeking Alpha - at Seeking Alpha - Wed Dec 31, 6:28AM CST
AmpliPhi BioSciences to Host Shareholder Update Conference Call
Business Wire - Tue Dec 30, 6:11PM CST
AmpliPhi BioSciences Corporation (OTCQB:APHB) ("AmpliPhi"
, the leader in the discovery and development of bacteriophage based therapies to treat drug resistant bacterial infections, today announced that it will host a shareholder update conference call on Monday, January 05, 2015 at 4:15 PM ET. XON: 40.86 (+0.78)
Intrexon Corporation Has Two Overlooked Opportunities In The Anti-Infective Space
Trevor Lowenthal - at Seeking Alpha - Mon Dec 29, 11:51AM CST
XON: 40.86 (+0.78), OGEN: 0.80 (-0.03)
Update: AmpliPhi Is Making Important Moves To Advance Its Anti-Infective Pipeline
Trevor Lowenthal - at Seeking Alpha - Fri Dec 26, 10:55PM CST
Acinetobacter Infections - Pipeline Review, H1 2014
M2 - Mon Dec 08, 3:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/5pbmng/acinetobacter) has announced the addition of the "Acinetobacter Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Acinetobacter Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acinetobacter Infections and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Acinetobacter Infections - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Acinetobacter Infections pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - AmpliPhi Biosciences - Melinta Therapeutics - Pfizer - Sarepta Therapeutics - Achaogen - Evolva - Novabiotics - Aridis Pharmaceuticals - FOB Synthesis - Synthetic Biologics - Trana Discovery - Cantab Biopharmaceuticals - Omnia Molecular - Northern Antibiotics - Nosopharm - Adenium Biotech - Vaxdyn For more information visit http://www.researchandmarkets.com/research/5p...netobacter
SYN: 1.88 (+0.01), SRPT: 15.40 (+0.19)
Update: AmpliPhi Q3 Earnings
Trevor Lowenthal - at Seeking Alpha - Wed Nov 19, 12:14AM CST
